iStopMM: The psychological effects of MGUS screening and changes to clinical presentation of myeloma

In this video, Sæmundur Rögnvaldsson, MD, PhD, of the University of Iceland in Reykjavik, Iceland, discusses the findings of the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) program, a large population-based screening study for monoclonal gammopathy of undetermined significance (MGUS), and a subsequent 3-arm randomized control trial. Screening in Iceland for MGUS resulted in patients with MM being diagnosed a year earlier on average. The levels of anxiety and depression were not found to have increased in these patients post-diagnosis, nor did they have decreased life satisfaction.